Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Phibro Animal Health

Phibro Animal Health (NASDAQ: PAHC) insider transactions

In the twelve months to 10 November 2026, executives and directors of Phibro Animal Health reported 100 open-market sales of 529,425 shares ($26.0m) and 1 open-market purchase of 10,000 shares ($317,700), by 3 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Phibro Animal Health shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
6 August 2026Bendheim Daniel MPresident and CEOGrant or award+11,699—15,177Form 4
6 August 2026Escudero Lisa AnnSee RemarksGrant or award+1,547—3,434Form 4
6 August 2026Bendheim JackExecutive ChairmanGrant or award+12,103—26,640Form 4
6 August 2026Weinstein JudithSee RemarksGrant or award+2,478—5,453Form 4
6 August 2026BENDHEIM JonathanDirectorGrant or award+2,716—5,984Form 4
6 August 2026Miller Larry LeeChief Operating OfficerGrant or award+3,522—38,071Form 4
6 August 2026David GlennChief Financial OfficerGrant or award+3,334—54,811Form 4
6 August 2026Rodriguez PatrickVP Finance and TreasurerGrant or award+1,503—1,503Form 4
4 August 2026Bendheim Daniel MPresident and CEOOther−486$36.603,478Form 4
4 August 2026David GlennChief Financial OfficerOther−840$36.6051,477Form 4
4 August 2026Weinstein JudithSee RemarksOther−472$36.602,975Form 4
4 August 2026Miller Larry LeeChief Operating OfficerOther−635$36.6034,549Form 4
4 August 2026Escudero Lisa AnnSee RemarksOther−265$36.601,887Form 4
4 August 2026Bendheim JackExecutive ChairmanOther−2,303$36.6014,537Form 4
29 May 2026Corcoran E ThomasDirectorOpen-market purchase+10,000$31.7741,459Form 4
7 May 2026Bendheim JackPresident and CEOOpen-market sale, 10b5-1 plan−1,350$47.5959,330Form 4
7 May 2026Bendheim JackPresident and CEOOpen-market sale, 10b5-1 plan−1,149$48.3158,181Form 4
7 May 2026Bendheim JackPresident and CEOOpen-market sale, 10b5-1 plan−2,029$49.1956,152Form 4
6 May 2026Bendheim JackPresident and CEOOpen-market sale, 10b5-1 plan−5,634$57.1862,086Form 4
6 May 2026Bendheim JackPresident and CEOOpen-market sale, 10b5-1 plan−1,406$58.1360,680Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Phibro Animal Health page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.